India is seeing a new surge in COVID-19 cases, with active cases reaching over 3,395 as of May 31 — nearly three times the number in a little over two weeks. Kerala, Maharashtra, and Delhi have turned into the biggest hotspots, even though health authorities continue to insist that severity is low. The increase, while not alarming in terms of hospitalizations, has seen India's health authorities keeping a closer watch with the identification of new Omicron subvariants and local clusters of cases.

With a sharp spike in active cases India is back on the global health radar. Though the numbers are still low compared to earlier waves, the rising trend in a number of states, along with the identification of new Omicron subvariants, is worth examining.

Also Read: Colon Cancer Is Rising In Millennials- But This One Symptom Still Feels Too Embarrassing To Talk About

India has witnessed an increase in active COVID-19 cases threefold in the last two weeks, from 1,010 on May 19 to 3,395 on May 31, with official government data. The rise is specifically prominent in Kerala, Maharashtra, and Delhi — regions that have typically been early warning signs of wider transmission trends within the country.

Kerala, which currently holds the highest number of active cases at 1,336, has seen a surge from just 430 cases reported on May 26. Maharashtra follows closely with 467 active cases, more than doubling from its 209 count just days ago. Delhi’s trajectory is also concerning, with a leap from 105 to 375 cases in the same period.

Although these figures are still small compared to the peak of the pandemic, the week-on-week surge suggests a possible first wave of transmission that is being watched closely by experts.

Also Read: Type 2 Diabetes And High Blood Pressure Now Affect 1 In 8 Americans, Study Links Combo To Early Death Risk

Covid Cases: The Current Clinical Scenario

As much as there has been an increase in case numbers, the severity of infection is still low, highlight the Indian health officials and experts. Majority of the patients are recovering under home isolation and only a few need hospitalization.

Official sources and the Indian Council of Medical Research (ICMR) indicated that there is "no cause for concern" in terms of public health emergency. ICMR Director General Dr. Rajiv Bahl provided assurances to the public, saying, "As of now, the severity is generally low. There's nothing to worry about. We should be vigilant and always be prepared."

This indicates that even as the rate of transmission could be increasing, the healthcare system is not getting strained, and the virus remains following a clinically milder pattern than in earlier waves.

Also Read: How “Safe” Vaping Is Hooking A New Generation On Nicotine?

Where Covid Cases Are Rising?

India's new COVID-19 scenario is extremely regionalized, with southern and western states witnessing initial hints of flare-ups prior to infections starting to rise in northern India.

Here's a closer examination of major states:

Kerala: From 430 cases on May 26 to 1,336 on May 31. Six fatalities have been reported.

Maharashtra: Cases went from 209 to 467; seven deaths have been reported.

Delhi: Triplication of cases, from 105 to 375, with three deaths.

Karnataka: From 47 to 234 active cases in under a week.

Tamil Nadu, Gujarat, Uttar Pradesh, West Bengal, Rajasthan, Madhya Pradesh, and Punjab have all experienced moderate increases.

These figures do not only reflect an increase in transmission but a geographical spread that crosses urban and semi-urban hubs, increasing the stakes for surveillance and containment.

Four COVID deaths in India in the past 24 hours — one in each of Delhi, Kerala, Karnataka, and Uttar Pradesh. Although deaths are still in single digits, the number of deaths in this new spike includes:

• Kerala (6 deaths since May 26)
• Maharashtra (7 deaths)
• Karnataka and Delhi (3 deaths each)
• Other states like Tamil Nadu, Gujarat, Rajasthan, Madhya Pradesh, and Punjab (1 death each)

With the present low rates of hospitalization and minimal clinical severity, these deaths are being assessed in the context of co-morbidities and age-related susceptibility.

Is Multi-Variant Spread Behind the Covid Surge In India?

Epidemiologists are particularly interested in understanding whether new variants may be fueling this latest uptick. According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), two new Omicron subvariants have been detected in India:

NB.1.8.1: Detected in Tamil Nadu in April

LF.7: Four cases detected in Gujarat in May

Globally, these variants have contributed to a rise in infections in Southeast Asian countries like Singapore, Hong Kong, and parts of China.

Still, the World Health Organization (WHO) now categorizes both NB.1.8.1 and LF.7 as "variants under monitoring" rather than "variants of concern" or "variants of interest." The WHO's current position is that:

"Based on the evidence available, the added public health risk from NB.1.8.1 is assessed as low at a global level."

The most common circulating strain in India is JN.1, with 53% of the sequenced cases, followed by BA.2 with 26%, while the rest of the 20% consists of other Omicron sublineages.

Covid-19: Surveillance and Public Health Strategy

India's response to the ongoing surge is being organized through the Integrated Disease Surveillance Programme (IDSP). The government is focusing on genomic sequencing, local containment strategies, and respiratory hygiene awareness.

Public health messaging remains on high alert but against panic. No restrictions on travel, lockdowns, or new public orders have been implemented thus far.

Dr. Bahl once again reinforced, "People do not need to take any immediate action. They should follow normal precautions. So, there is nothing special to do right now."

That means maintaining current best practices like handwashing, mask-wearing in close indoor environments, and self-isolation when symptomatic.

Covid-19: Should the World Be Concerned Now?

For the global community, India's recent development is a reminder of the unpredictable nature of the pandemic. Although the world has largely left behind COVID-19 as an emergency, localized outbreaks in densely populated areas like India can ripple outward — particularly if emerging variants start to demonstrate greater transmissibility or immune escape.

The positive news still is that vaccines continue to provide strong protection against severe illness, and India's national immunization program has maintained high coverage in adult groups. However, ongoing genomic surveillance and real-time data transparency will remain crucial to avert larger outbreaks.

India's COVID-19 surge, while of limited magnitude and clinical severity, is a multifaceted convergence of regional patterns of transmission, emerging variant sequences, and preparedness in public health. With cases being largely mild and mortality rates low, the nation's health care system is still in hand but not resting on its laurels.

In the meantime, there is no cause for global alarm. Nevertheless, India's experience should prompt health systems everywhere to remain on high alert, keep genomic surveillance going, and inform the public in a transparent manner. The virus is evolving, but so is our combined ability to deal with it.

New Zealand has stepped up surveillance after the first detection of a dengue and Zika-carrying mosquito larvae in the country.

The larval species was confirmed as 'Aedes aegypti' — known to carry diseases including dengue fever, yellow fever, Zika, and chikungunya, across the globe.

As New Zealand does not normally have the mosquito species, the larvae detected were counted as "exotic".

The mosquito species did not cause any outbreak, but were spotted during a routine surveillance program in Auckland.

"The National Public Health Service has commenced a heightened surveillance and interception programme following mosquito larvae being collected from a routine surveillance trap at Queens Wharf, Auckland, on Monday 30 March," Health New Zealand said in a statement.

Health New Zealand reported that exotic species were occasionally found at ports and airports.

Not A Public Threat Yet

The health body noted that the larvae were not considered a public health or biosecurity threat yet because there was no indication they had become established.

But the agency aimed to continue "intensive monitoring for at least three weeks".

"The monitoring would take place within a 400m radius of the site where the larvae were identified. Health Protection Officers would place mosquito traps in the survey area," the statement said.

"These have been hidden away from plain sight so they are not disturbed, for example, in old tyres, bushes, or pools of water. We ask members of the public to avoid touching or disturbing these traps if they find them, as it may disrupt our monitoring and trapping efforts," medical officer of health Dr David Sinclair said.

Sinclair said New Zealanders were most at risk from diseases transmitted by mosquitoes when travelling overseas, including to Pacific Island countries and territories where dengue fever was known to be present.

Dengue Surging In 17 Countries

The US Centers for Disease Control and Prevention recently issued a travel alert of dengue outbreaks across 17 countries.

The CDC alert issued on March 23 identified 17 countries reporting an increased number of cases of dengue. These include: Afghanistan, Bangladesh, Bolivia, Colombia, Cook Islands, Cuba, Guyana, Maldives, Mali, Mauritania, New Caledonia, Pakistan, Samoa, Sudan, Timor-Leste, Vietnam, and the United States territories of American Samoa, Puerto Rico, and the US Virgin Islands, where local transmission is already common.

Also read: Long-term Exposure To Air Pollution Increases Fatality Rates In Dengue: Study

What Is Dengue?

Dengue is a disease caused by a virus spread through mosquito bites. It is transmitted through infected mosquitoes, primarily the species Aedes aegypti.

The breakbone fever is caused by an infection with any of four different dengue viruses. These include:

• Dengue virus type 1 (DENV-1 or DEN-1)

• Dengue virus type 2 (DENV-2 or DEN-2)

• Dengue virus type 3 (DENV-3 or DEN-3)

• Dengue virus type 4 (DENV-4 or DEN-4)

Also read: New dengue vaccine over 80% effective, prevents severe disease for up to 5 years

Common Symptoms of dengue include:

• Sudden onset of high-grade fever.

• Intense headache

• Severe muscle, joint, or bone pain.

• Skin Rash that often appears 2–5 days after the fever starts

• Nausea and Vomiting

• Minor bleeding

• Fatigue.

The COVID Cicada variant, currently circulating in 23 countries, is likely to affect children more than the previous variants.

Children have largely escaped severe illness from the SARS-COV-2 virus.

However, the new Cicada variant with around 75 genetic changes in its spike protein is likely to disproportionately affect children, as per an expert, who noted its presence in the UK.

“Some people have done analysis on this, suggesting it may be more prevalent among young children. Children get infections all the time, but this might be something to do with the fact that they have never been exposed to Covid vaccines," Prof Ravindra Gupta, of Cambridge University, who advised the UK government during the pandemic, was quoted as saying to The Mirror.

“So this is something we’re looking at in the lab to try and work out why. The problem with this is that it is an infection that spreads fast. Eventually, it ends up in someone vulnerable," he added.

Key Symptoms

Symptoms seem to be similar to those of other recent variants and include

• sore throat,
• cough,
• congestion,
• fatigue,
• headache
• fever.

Also read: Cicada Variant: Will The Current COVID Vaccine Provide Protection?

What Do The 75 Genetic Changes Mean?

Cicada, a descendant of the Omicron variant that emerged in 2021, was first detected in South Africa in 2024. However, it disappeared soon after, only to emerge early this year.

Prof Gupta told the publication that “the Cicada variant developed the 75 mutations to escape immunity, and it evolved by incubating a single patient for over a year”.

"This 'patient zero' would have been unable to clear the virus due to a compromised immune system," due to HIV or anti-cancer drugs.

Further, he explained that due to 75 mutations to the spike protein, the body’s antibodies will take a longer time to fight the Cicada variant.

However, there is no evidence yet that it is likely to cause more severe disease.

Will The Cicada Variant Cause Severe Illness?

The Cicada variant is particularly concerning as it provides no immune protection to people with previous infection or even vaccination.

Yet, the World Health Organization and health experts advise that existing COVID vaccinations can help prevent severe illness and hospitalization.

"It would appear that all the protections we have from our experience with the virus and with vaccines probably offer more limited—not zero—but more limited protection against this strain," Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, was quoted as saying by Time.

Also read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?

How To Safeguard

Dr. Sai Balasubramanian, a doctor and healthcare strategy executive, writing in Forbes, stressed the need to follow COVID practices such as masks and hand hygiene.

"Healthcare professionals recommend taking general precautions, similar to those used to prevent most viral transmission: get vaccinations when appropriate, wear masks in crowded areas or indoors where there is a high risk of transmission," he said.

He also urged “avoid individuals who have known illness or infections, wash hands frequently, and continue to stay apprised of local community guidelines and the infection spread”.

GLP-1 drugs are powerful tools that can improve health, but it comes with risks and caveats. While these are medical therapies, they are being misused as cosmetic products by cosmetologists, physiotherapists, dermatologists, among others.

To curb its misuse and improve public health, the Indian government today issued guidelines on its use, while also flagging risks around it.

In an official statement issued today, the government has stated that it will roll out stricter inspections to curb the misuse of GLP-1 drugs in the country and will punish those who violate the rules.

“GLP-1 drugs are a significant medical breakthrough in treating type 2 diabetes and obesity, but they are not without risk. The drugs carry a wide range of side effects - from common symptoms like nausea and vomiting to severe complications including pancreatitis, kidney injury, and bowel obstruction. These risks make it essential that GLP-1 drugs are only taken under the supervision of registered medical practitioners/specialists,” the statement said.

In the wake of its hype over weight loss, the country's regulatory authorities have taken firm steps to prevent unsupervised use and malpractices in the supply chain.

It has “strongly advised” patients and the public to” consult a qualified medical specialist before use, and to obtain these medications with prescription only through legitimate, regulated channels”.

“Stricter inspections and surveillance will continue in the coming weeks. Businesses that break the rules will face license cancellation, fines, and legal action,” the statement said.

Also read: GLP-1 Drugs: Why India Needs Stricter Rules Now

What Are The Side-effects Of GLP-1 Drugs?

GLP-1 drugs work to keep food in the digestive system for longer – making people feel fuller for longer, thus reducing appetite and inducing weight loss. Hence, the drugs are also prescribed to people with obesity.

However, when done without clinical oversight, it can lead to severe health complications.

There are various side effects to taking GLP-1 drugs, including nausea and dizziness, to pancreatitis and medullary thyroid cancer.

Some serious side effects include

• Pancreatis
• Thyroid Cancer
• Acute (Sudden) Kidney Injury
• Worsening Diabetes-Related Retinopathy
• Gallstone & Bile Duct Blockage
• Rapid loss of fat in the face
• Wrinkles
• Sunken eyes

GLP-1 medications may also complicate various health conditions, such as allergic reactions, with shortness of breath and low blood sugar.

Rush For Generic Weight Loss Drugs

The government's advisory comes as patent for semaglutide -- an active ingredient in diabetes and anti-obesity drugs, specifically Wegovy and Ozempic -- expired on March 20.

This has led to a rush among Indian pharma companies to launch cheaper generic versions, significantly increasing affordability and access for millions battling Type 2 diabetes and obesity.

Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs

Major Indian drugmakers who launched their generic semglutide injection in the country in March include Sun Pharmaceutical Industries, Zydus Lifesciences, Alkem Laboratories, and Dr. Reddy’s Laboratories.

WHO Guidelines on GLP-1 drugs

Amid the increasing prevalence of GLP-1 drugs, the World Health Organisation (WHO), late last year, acknowledged its role in treating obesity.

However, it warned that medications like GLP-1 alone will not solve the problem affecting more than one billion people worldwide.

The global health body also issued conditional recommendations for using these therapies as part of a comprehensive approach that includes healthy diets, regular physical activity, and support from health professionals.